Back to Results
First PageMeta Content
Inotrope / Heart failure / Claudio Cavazza / Biology / Anatomy / Heart diseases / Sigma-Tau


THE DEBIOPHARM GROUP AND SIGMA-TAU SIGN R&D AND COMMERCIAL AGREEMENT FOR ISTAROXIME IN ACUTE HEART FAILURE SYNDROMES Lausanne, Switzerland, June 13, 2006 – The Debiopharm Group (Debiopharm), a global
Add to Reading List

Document Date: 2009-02-11 09:35:11

Open Document

File Size: 29,70 KB

Share Result on Facebook

City

Rome / Lausanne / Pomezia / /

Company

Novartis / The Debiopharm Group / Pharmaceuticals Inc. / Industrie Farmaceutiche Riunite SpA / Debiopharm Contacts Kim Bill / /

Country

Germany / Switzerland / Netherlands / Italy / Sudan / France / United States / Portugal / United Kingdom / China / Spain / /

Currency

USD / EUR / /

/

Event

Business Partnership / Labor Issues / /

/

IndustryTerm

biopharmaceutical development / treatment of heart failure / biopharmaceutical development company specialising / pharmaceutical / treatment for systolic and diastolic dysfunction / pharmaceutical partners / manufacturing / treatment of acute heart failure / /

MedicalCondition

Rare Diseases / left ventricular dysfunction / systolic and diastolic dysfunction / acute heart failure / congestive heart failure / disease / chronic heart failure / severe heart disease / heart failure / /

MedicalTreatment

Chinese Traditional Medicine / relaxation / /

Organization

Republicans / /

Person

Rolland-Yves Mauvernay / Claudio Cavazza / Federica Tommasini / Wendy Lau / /

/

Position

Sigma-Tau Contacts Paolo Carminati Head / Chairman / President and CEO / Executive / VP Business Development & Licensing / /

ProvinceOrState

Maryland / /

Technology

its products / drug delivery / its / /

URL

www.debiopharm.com / /

SocialTag